← back to search

Cédric Rébé

La Ligue Contre le Cancer · FR
Area of research
Immunology · Oncology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immune cells in cancer, Immune Cell Function and Interaction, and Inflammasome and immune disorders.
h-index
48
citations
9,783
works
145
NIH funding
primary concept
Medicine
email

Recent publications

The double face of IL-1β in lung cancer.
2026cited by 0position: contributordoi
Interleukin-1β and cancer immune response
Seminars in Immunology 2025cited by 6position: contributordoi
Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer.
2025cited by 2position: contributordoi
Supplementary Table S1 from Associating Immunotherapy and Targeted Therapies: Facts and Hopes
2025cited by 0position: contributordoi
Data from Associating Immunotherapy and Targeted Therapies: Facts and Hopes
2025cited by 0position: contributordoi
Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical application.
2024cited by 13position: contributordoi
Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, <i>KEAP1/STK11</i> co-mutated metastatic NSCLC.
2024cited by 0position: contributordoi
Associating Immunotherapy and Targeted Therapies: Facts and Hopes.
2023cited by 7position: contributordoi
Data from Associating Immunotherapy and Targeted Therapies: Facts and Hopes
2023cited by 0position: contributordoi
Supplementary Table S1 from Associating Immunotherapy and Targeted Therapies: Facts and Hopes
2023cited by 0position: contributordoi
Supplementary Table S1 from Associating Immunotherapy and Targeted Therapies: Facts and Hopes
2023cited by 0position: contributordoi
Supplementary Table S1 from Associating Immunotherapy and Targeted Therapies: Facts and Hopes
2023cited by 0position: contributordoi
Data from Associating Immunotherapy and Targeted Therapies: Facts and Hopes
2023cited by 0position: contributordoi
Supplementary Table S1 from Associating Immunotherapy and Targeted Therapies: Facts and Hopes
2023cited by 0position: contributordoi
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.
2022cited by 182position: contributordoi
Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses.
2022cited by 78position: contributordoi
Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment.
2022cited by 40position: contributordoi
Downregulation of Elovl5 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF-β receptors.
2022cited by 27position: contributordoi
Can the hyperthermia-mediated heat shock factor/heat shock protein 70 pathway dampen the cytokine storm during SARS-CoV-2 infection?
2022cited by 8position: contributordoi
Editorial: Inflammasomes: Cornerstone of Immunity.
2022cited by 0position: contributordoi
NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer.
2021cited by 144position: contributordoi
Follicular helper-T cells restore CD8&lt;sup&gt;+&lt;/sup&gt;-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy.
2021cited by 93position: contributordoi
Interleukin-1β and Cancer.
2020cited by 239position: contributordoi
Cathepsin B Is Required for NLRP3 Inflammasome Activation in Macrophages, Through NLRP3 Interaction.
2020cited by 148position: contributordoi
Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study.
2020cited by 85position: contributordoi
Interplay between Liver X Receptor and Hypoxia Inducible Factor 1α Potentiates Interleukin-1β Production in Human Macrophages.
2020cited by 47position: contributordoi
Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
2020cited by 28position: contributordoi
Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency.
2020cited by 19position: contributordoi
Heat shock and HSP70 regulate 5-FU-mediated caspase-1 activation in myeloid-derived suppressor cells and tumor growth in mice.
2020cited by 15position: contributordoi
STAT3, a Master Regulator of Anti-Tumor Immune Response.
2019cited by 107position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

François Ghiringhelli · Peuplements végétaux et bioagresseurs en milieu tropical29 papers (2019–2026) · 26 papers (2019–2026)Sylvain Ladoire · Université de franche-comté12 papers (2012–2025)Valentin Dérangère · Centre Georges François Leclerc9 papers (2012–2022) · 9 papers (2023–2025)Emeric Limagne · Université Bourgogne Franche-Comté6 papers (2019–2024)Carmen Garrido · Laboratoire de Recherche Vasculaire Translationnelle4 papers (2019–2022)Lionel Apetoh · Centre d'Étude des Pathologies Respiratoires2 papers (2019–2022)Frederique Vegran · Centre de recherche Translationnelle en Médecine moléculaire2 papers (2021–2022)Nicolas Roussot · Centre de recherche Translationnelle en Médecine moléculaire2 papers (2022–2025)Stephane Perrey · Digital Health Cooperative Research Centre2 papers (2019–2022)David Masson · Centre d’Investigation Clinique Innovation Technologique de Nancy2 papers (2020–2022)Simon C. Robson · Harvard University1 papers (2012–2012)François Ghiringhelli · Peuplements végétaux et bioagresseurs en milieu tropical1 papers (2012–2012)Frédérique Végran · University of Lausanne1 papers (2012–2012)Angélique Chevriaux · University of Lausanne1 papers (2012–2012)Grégoire Mignot · University of Lausanne1 papers (2012–2012)Alfred Zippelius · University of Basel1 papers (2025–2025)Fanny Chalmin · University of Lausanne1 papers (2012–2012)Laurent Arnould · Siemens (Germany)1 papers (2022–2022)